Disease · MONDO_0001347
Comparisons in its trials15
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 15 of 15
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Part A: Losmapimod 15 Milligrams (mg) vs Part A: Placebo: Part A: Number of Participants With Clinically Significant Changes in Vital Parameters | 0 of 130 | 0 of 130 | 260 | NCT05397470 | Trial comparisons |
| Part A: Losmapimod 15 Milligrams (mg) vs Part A: Placebo: Part A: Number of Participants With Clinically Significant Changes in Physical Examinations | 0 of 130 | 0 of 130 | 260 | NCT05397470 | Trial comparisons |
| Part A: Losmapimod 15 Milligrams (mg) vs Part A: Placebo: Part A: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters | 0 of 130 | 0 of 130 | 260 | NCT05397470 | Trial comparisons |
| Part A: Losmapimod 15 Milligrams (mg) vs Part A: Placebo: Part A: Number of Participants With Clinically Significant Changes in Urinalysis | 0 of 130 | 0 of 130 | 260 | NCT05397470 | Trial comparisons |
| Part A: Losmapimod 15 Milligrams (mg) vs Part A: Placebo: Part A: Number of Participants With Clinically Significant Changes in Hematology Parameters | 0 of 130 | 0 of 130 | 260 | NCT05397470 | Trial comparisons |
| Part A: Losmapimod 15 Milligrams (mg) vs Part A: Placebo: Part A: Number of Participants With Clinically Significant Changes in Clinical Chemistry Parameters | 0 of 130 | 0 of 130 | 260 | NCT05397470 | Trial comparisons |
| Losmapimod 15 Milligrams (mg) Twice Daily (BID) vs Placebo: Number of Participants With Adverse Events of Special Interest (AESIs) | 0 of 40 | 0 of 40 | 80 | NCT04003974 | Trial comparisons |
| Losmapimod 15 Milligrams (mg) Twice Daily (BID) vs Placebo: deaths from any cause | 0 of 40 | 0 of 40 | 80 | NCT04003974 | Trial comparisons |
| Losmapimod 15 Milligrams (mg) Twice Daily (BID) vs Placebo: Number of Participants Who Prematurely Discontinued Study Drug Due to a Treatment Emergent Adverse Event (TEAE) | 0 of 40 | 0 of 40 | 80 | NCT04003974 | Trial comparisons |
| Losmapimod 15 Milligrams (mg) Twice Daily (BID) vs Placebo: serious adverse events | 2 of 40 | 0 of 40 | 80 | NCT04003974 | Trial comparisons |
| Group A - FSHD vs Group B - LGMD2B and FSHD: Number of Participants With Vital Sign Abnormality Resulting in a TEAE | 0 of 4 | 3 of 14 | 18 | NCT02579239 | Trial comparisons |
| Group A - FSHD vs Group B - LGMD2B and FSHD: Number of Participants With a Clinical Laboratory Abnormality Leading to an AE | 0 of 4 | 4 of 14 | 18 | NCT02579239 | Trial comparisons |
| Group A - FSHD vs Group B - LGMD2B and FSHD: Number of Participants With a Clinically Significant Pulmonary Function Event Resulting in a TEAE | 0 of 4 | 0 of 14 | 18 | NCT02579239 | Trial comparisons |
| Group A - FSHD vs Group B - LGMD2B and FSHD: Number of Participants With a Clinically Significant Electrocardiogram (ECG) Abnormality Leading to a TEAE | 0 of 4 | 0 of 14 | 18 | NCT02579239 | Trial comparisons |
| Group A - FSHD vs Group B - LGMD2B and FSHD: serious adverse events | 0 of 4 | 0 of 14 | 18 | NCT02579239 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001347/comparisons